Kenneth G. Schuler

Emily C. Melvin

Richard L. Horwitz

David E. Moore

Bindu Ann George Palapura

Michael R. Seringhaus

Timothy J. O'Brien

Jack B. Blumenfeld

Karen Jacobs

Daniel J. Klein

Nicholas N. Kallas

Nicholas Groombridge

Eric A. Stone

Daniel M. Silver

Christina Schwarz

Ethan H. Townsend

Kira A. Davis

Josephine Young

Jason L. Meizlish

ANDA triggers Novartis suit to block generic FANAPT®, defending a reissue patent on the `iloperidone` antipsychotic compound vital for schizophrenia care.

Prosecution History analysis

Examiner Search analysis

Invalidity Framework analysis

Name	Ratings
Vanda Pharmaceuticals Inc	L3 A
Aventisub LLC	L5 E
Novartis Pharmaceuticals Corp	L4 A
Novartis Pharma AG	L4 A

Name	Ratings
Morris Nichols Arsht & Tunnell LLPLocal	L5 A
Jack B. Blumenfeld	L5 A
Karen Jacobs	L4 A
Ethan H. Townsend	L1 B
Fitzpatrick Cella Harper & Scinto	L4 A
Nicholas N. Kallas	L2 C
McCarter & English LLP	L4 A
Daniel M. Silver	L4 A
Venable LLP	L4 A
Christina Schwarz	L2 D
Paul Weiss Rifkind Wharton Garrison LLP	L2 C
Nicholas Groombridge	L5 B
Josephine Young	L1 C
Eric A. Stone	L1 D
Daniel J. Klein	-- -- --
Kira A. Davis	-- -- --
Jason L. Meizlish	-- -- --

Name	Ratings
Potter Anderson & Corroon LLPLocal	L5 A
Richard L. Horwitz	L5 A
David E. Moore	L5 A
Bindu Ann George Palapura	L4 C
Latham & Watkins LLP	L4 A
Emily C. Melvin	L3 D
Kenneth G. Schuler	L3 E
Timothy J. O'Brien	L1 D
Michael R. Seringhaus	-- -- --

1:13-cv-01973

Vanda Pharma Inc v. Roxane Laboratories Inc